CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment.
Journal
NPJ Parkinson's disease
ISSN: 2373-8057
Titre abrégé: NPJ Parkinsons Dis
Pays: United States
ID NLM: 101675390
Informations de publication
Date de publication:
24 Apr 2023
24 Apr 2023
Historique:
received:
20
11
2022
accepted:
05
04
2023
medline:
25
4
2023
pubmed:
25
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Pathophysiological substrate(s) and progression of Parkinson's disease (PD) with mild cognitive impairment (PD-MCI) are still matter of debate. Baseline cerebrospinal fluid (CSF) neurochemical profile and cognitive changes after 2 years were investigated in a retrospective series of PD-MCI (n = 48), cognitively normal PD (PD-CN, n = 40), prodromal Alzheimer's disease (MCI-AD, n = 25) and cognitively healthy individuals with other neurological diseases (OND, n = 44). CSF biomarkers reflecting amyloidosis (Aβ42/40 ratio, sAPPα, sAPPβ), tauopathy (p-tau), neurodegeneration (t-tau, NfL, p-NfH), synaptic damage (α-syn, neurogranin) and glial activation (sTREM2, YKL-40) were measured. The great majority (88%) of PD-MCI patients was A-/T-/N-. Among all biomarkers considered, only NfL/p-NfH ratio was significantly higher in PD-MCI vs. PD-CN (p = 0.02). After 2 years, one-third of PD-MCI patients worsened; such worsening was associated with higher baseline levels of NfL, p-tau, and sTREM2. PD-MCI is a heterogeneous entity requiring further investigations on larger, longitudinal cohorts with neuropathological verification.
Identifiants
pubmed: 37095141
doi: 10.1038/s41531-023-00509-w
pii: 10.1038/s41531-023-00509-w
pmc: PMC10126070
doi:
Types de publication
Journal Article
Langues
eng
Pagination
68Informations de copyright
© 2023. The Author(s).
Références
Mov Disord. 2014 Jul;29(8):1019-27
pubmed: 24436092
Am J Pathol. 2014 Apr;184(4):966-975
pubmed: 24625392
J Alzheimers Dis. 2016 Aug 18;54(1):287-95
pubmed: 27567832
Neurodegener Dis Manag. 2015 Oct;5(5):425-43
pubmed: 26517759
JAMA Neurol. 2019 Mar 1;76(3):318-325
pubmed: 30508027
BMC Neurol. 2014 May 22;14:113
pubmed: 24884485
Dement Geriatr Cogn Disord. 2019;47(4-6):187-197
pubmed: 31315127
Mov Disord. 2011 Jul;26(8):1428-35
pubmed: 21469206
Neurology. 2018 Sep 4;91(10):e894-e905
pubmed: 30089615
Parkinsonism Relat Disord. 2018 Apr;49:4-8
pubmed: 29409704
Mov Disord. 2016 Oct;31(10):1535-1542
pubmed: 27548849
Mov Disord. 2014 Apr 15;29(5):634-50
pubmed: 24757112
PLoS One. 2021 Oct 7;16(10):e0257372
pubmed: 34618817
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Brain. 1999 May;122 ( Pt 5):871-82
pubmed: 10355672
Mov Disord. 2014 Nov;29(13):1599-605
pubmed: 25258345
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Acta Neuropathol. 2010 Dec;120(6):827-8
pubmed: 20838798
Brain. 2020 Mar 1;143(3):932-943
pubmed: 32065223
Neurology. 2009 Dec 1;73(22):1914-22
pubmed: 19949037
J Parkinsons Dis. 2015;5(4):783-92
pubmed: 26599300
Int J Neurosci. 2015;125(9):645-54
pubmed: 25202803
J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):83-86
pubmed: 35944974
Mov Disord. 2016 Jun;31(6):898-905
pubmed: 26878815
Mov Disord. 2013 Mar;28(3):302-10
pubmed: 23408705
Mov Disord. 2010 Nov 15;25(15):2682-5
pubmed: 20818673
Mov Disord. 2020 Mar;35(3):513-518
pubmed: 31837067
Neurology. 2014 Jan 28;82(4):308-16
pubmed: 24363137
EMBO Mol Med. 2016 May 02;8(5):466-76
pubmed: 26941262
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Ann Clin Transl Neurol. 2017 Aug 31;4(10):700-713
pubmed: 29046879
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
JAMA Neurol. 2013 May;70(5):580-6
pubmed: 23529397
Mov Disord. 2012 Aug;27(9):1125-8
pubmed: 22692724
Neurology. 2010 Sep 21;75(12):1055-61
pubmed: 20720189
Neurology. 2017 Feb 21;88(8):767-774
pubmed: 28108638
Parkinsonism Relat Disord. 2015 Mar;21(3):271-6
pubmed: 25596881
Neurology. 2016 Mar 1;86(9):829-35
pubmed: 26826204
Alzheimers Dement (Amst). 2021 Jun 29;13(1):e12214
pubmed: 34222611
Diagnostics (Basel). 2020 Nov 26;10(12):
pubmed: 33256252
Neurology. 2017 Oct 24;89(17):1782-1788
pubmed: 28939668
Acta Neuropathol. 2018 Sep;136(3):363-376
pubmed: 29700597
Mol Cell Proteomics. 2016 Oct;15(10):3126-3138
pubmed: 27507836
Front Aging Neurosci. 2022 Jun 16;14:892493
pubmed: 35783125
Front Aging Neurosci. 2014 Mar 31;6:53
pubmed: 24744728
JAMA Neurol. 2015 Oct;72(10):1175-82
pubmed: 26258692
Ann Neurol. 2012 Oct;72(4):587-98
pubmed: 23037886
Mov Disord. 2020 May;35(5):845-850
pubmed: 32034933
Mov Disord. 2020 Jul;35(7):1138-1144
pubmed: 32445500
J Neural Transm (Vienna). 2016 Apr;123(4):431-8
pubmed: 26852137
J Alzheimers Dis. 2020;76(3):1171-1178
pubmed: 32597810
Mov Disord. 2021 Dec;36(12):2945-2950
pubmed: 34480363
J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881
pubmed: 30967444
Transl Neurodegener. 2017 Sep 13;6:24
pubmed: 28919975
Neurology. 2015 Jan 6;84(1):57-63
pubmed: 25411441
Mov Disord. 2004 Sep;19(9):1020-8
pubmed: 15372591
Lancet Neurol. 2019 Jun;18(6):573-586
pubmed: 30981640
Mov Disord. 2017 Oct;32(10):1389-1400
pubmed: 28880418
Neuropsychol Rev. 2022 Mar;32(1):149-160
pubmed: 33860906
Mov Disord. 2023 Feb;38(2):267-277
pubmed: 36504237
NPJ Parkinsons Dis. 2017 Feb 8;3:7
pubmed: 28649607
Mov Disord. 2012 Mar;27(3):349-56
pubmed: 22275317
Mov Disord. 2022 Apr;37(4):669-683
pubmed: 35122299
Nat Rev Dis Primers. 2021 Jul 1;7(1):47
pubmed: 34210995